NYU Langone Health
VC Fund
New York, United States
NYU Langone Health is a nonprofit organization that provides a center of excellence in healthcare, research, and medical education.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries NYU Langone Health invests in
Stages NYU Langone Health invests in
Countries NYU Langone Health invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan G. Harris
|
|||
Joseph J. Greco
|
|||
Adi Mashiach
|
|||
Alison Bateman-House
|
|||
A Reza Radjabi
|
|||
| See all 13 contacts → | |||
Investment Focus
Industry
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Product Research 1 (33%)
Stage
- Series A 1 (33%)
- Venture - Series Unknown 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alan G. Harris
Adjunct Professor of Medicine
|
Adjunct Professor of Medicine | Total investments: 0 | Find email | |
|
Joseph J. Greco
SVP, Chief of Hospital Operations NYU Winthrop
|
SVP, Chief of Hospital Operations NYU Winthrop | Total investments: 0 | Find email | |
|
Adi Mashiach
Guest Lecturer
|
Guest Lecturer | Total investments: 0 | Find email | |
|
Alison Bateman-House
Chair, Compassionate Use Advisory Committee (CompAC) Infectious Diseases (ID)
|
Chair, Compassionate Use Advisory Committee (CompAC) Infectious Diseases (ID) | Total investments: 0 | Find email | |
|
A Reza Radjabi
Private Attending
|
Private Attending | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aethon Therapeutics
|
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. | $30M / Series A / Jan 09, 2023 | |
|
Aethon Therapeutics
|
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations. | $30M / Series A / Jan 09, 2023 | |
Ajax Therapeutics
|
Ajax Therapeutics develops targeted therapies for hematologic cancers, with a focus on treating myeloproliferative neoplasms through precision drug discovery approaches. The company applies computational chemistry and structural biology to design small-molecule therapies that selectively target disease-driving proteins while minimizing off-targeteffects. Its research centers on next-generation inhibitors of the JAK2 protein, a key driver of certain blood cancers, using a differentiated mechanism that binds the Type II conformation of the kinase. This approach aims to improve treatment effectiveness and address limitations of existing therapies that provide symptom relief but do not fully suppress disease progression. It integrates discovery, preclinical research, and clinical development within its operating model, enabling continuous refinement of drug candidates based on biological insights and trial data. It collaborates with research institutions and leverages scientific expertise in oncology and molecular medicine to support development efforts. | $40M / Venture - Series Unknown / Jun 01, 2021 |
Co-Investors
Apple Tree Partners
6 deals together
Boxer Capital
1 deal together
EcoR1 Capital
1 deal together
Memorial Sloan - Kettering Cancer Center
1 deal together
Schrödinger
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does NYU Langone Health invest in?
NYU Langone Health invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NYU Langone Health?
Public channels for NYU Langone Health include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NYU Langone Health?
The team at NYU Langone Health includes Alan G. Harris (Adjunct Professor of Medicine), Joseph J. Greco (SVP, Chief of Hospital Operations NYU Winthrop) and Adi Mashiach (Guest Lecturer), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
